

Genetics Access Pilot (GAP) Project

An ACS Cancer Programs National Quality Improvement Pilot

Kick off Call January 31, 2025



Logistics

- Please mute yourself!
- Don't put us on hold!
- This meeting is being recorded but will NOT be posted publicly; a copy of slides can be obtained by emailing cancerqi@facs.org
- Reach out to <u>cancerqi@facs.org</u> with questions, comments, suggestions, or feedback



Agenda

- Welcome
- Introduce Project Team
- Overview of Project
- Program Introduction
- Q &A and Adjourn



Introducing our Project Team Leads



Lee Wilke, MD, FACS
Senior Medical Director, Clinical Cancer
Hendricks Chair in Breast Cancer Surgery
UW Health/UW Carbone Cancer Center



Kathy Yao, MD, MS, FACS
Vice Chair, Research and
Development Director, Breast
Cancer Research
NorthShore University
HealthSystem
Clinical Professor of Surgery
Pritzker School of Medicine,
University of Chicago



GAP Project Team

- Christine Jett-CGC
- Anthony (Tony) Yang-CoC QIC Vice Chair
- Sue Freidman-Advocate
- Cary Kaufman-Breast Surgeon
- Tony Nguyen-Breast Surgeon
- Jill Dietz-Breast Surgeon

- Meeghan Lautner –Breast Surgeon
- Ton Wang-Implementation
- Kelley Chan-CP Scholar
- Eileen Reilly-Quality Manager
- Tashea (Shea) Coates-QIS



GAP Goals and Objectives

- Goal: This pilot project seeks to better understand effective models for and barriers to offering genetic testing to newly diagnosed breast cancer patients.
- Aim: Increase the number of newly diagnosed breast cancer patients offered genetic testing by 20% from baseline at CoC/NAPBC pilot sites from January 2025 to December 2025

Secondary Aims:

- Obtain baseline data of genetic testing in pilot sites for proposed population
- Identify structural and process barriers to achieve testing
- Develop and test interventions to address modifiable barriers to genetic testing
- Spread, scale, and disseminate findings

Timeline



Date	Event
Nov 20	Informational webinar at 12pm CT
December 20	Applications are Due at 11:59p CT
Jan 15	Applicants are notified of their selection status
Jan 31	Applicant kick off call
Feb 28	Pre-survey and chart review data due -20 patients seen Oct 1-Dec 31, 2023
April 15	Patients seen Jan 1-March 31, 2025 data due
April 25	Cohort Call
July 15	Patients seen April 1-June 31 data due
August 22	Cohort Call
Oct 15	Patients seen July 1-Sept 30 data due
Nov 14	Cohort call
Dec 15	Patients seen Oct 1- Nov 30 data due Potential wrap up/summary call



Data and Quality Improvement

For year 1: How much time is required?

We approximate 15-20 hours of time per year will be spent on:

- Submitting 1 pre and 1 post survey
- Submitting 4 rounds of data submission
- Attending/viewing up to 4 webinars and/or group calls with programs in your cohort

This time does not include any team huddles/meetings or time spent on PDSA cycles or collecting information






What are we measuring?

Description/ Definition	Measure Calculation (Numerator:/Denominator:)	Data Source Associated Data Collection Tool
% of newly diagnosed breast cancer patients diagnosed with triple negative offered genetic testing	Numerator: Number of patients diagnosed with triple negative breast cancer offered genetic testing Denominator: All newly diagnosed breast cancer patients diagnosed with triple negative breast cancer	Review of Patient Health Records
% of newly diagnosed breast cancer patients 51-65 years old offered genetic testing	Numerator: Number of patients aged 51-65 offered genetic testing Denominator: All newly diagnosed breast cancer patients between ages 51-65	Review of Patient Health Records
% of newly diagnosed breast cancer patients aged 50 and younger offered genetic testing	Numerator: Number of patients aged 50 and younger offered genetic testing Denominator: All newly diagnosed breast cancer patients aged 50 and younger	Review of Patient Health Records

[©] American College of Surgeons 2023. Content may not be reproduced or repurposed without the written permission of the American College of Surgeons.

How would we submit data?

- REDCap is a web-based interface secure to the American College of Surgeons.
- You do not need to purchase software to enter data into REDCap
- A link will be sent to the primary contact's email at all data collection intervals



What data will we submit? Pre-Survey and Chart Review Data

- Pre survey
 - 7 questions
 - Will ask about current model for genetic testing
 - Available resources
- Chart Review data: Up to 20 case review forms per time period (Baseline is patients seen Oct-Dec 2023)
 - Accession number, if available
 - Age
 - Sex
 - Race and ethnicity
 - Patient Zip Code
 - Histology
 - Receptor Status
 - Family History
 - Testing offered?

ACS Cancer Programs has submitted an IRB application for exempt/non-human subjects research status, and the exemption has been granted.

Program Introduction (1 min)

- Introduce yourself, your QI team, facility name and location
- What strengths is your program bringing to this collaborative?
- What do you hope to accomplish over the course of the year?

Timeline



Date	Event
Nov 20	Informational webinar at 12pm CT
December 20	Applications are Due at 11:59p CT
Jan 15	Applicants are notified of their selection status
Jan 31	Applicant kick off call
Feb 28	Pre-survey and chart review data due -20 patients seen Oct 1-Dec 31, 2023
April 15	Patients seen Jan 1-March 31, 2025 data due
April 25	Cohort Call
July 15	Patients seen April 1-June 31 data due
August 22	Cohort Call
Oct 15	Patients seen July 1-Sept 30 data due
Nov 14	Cohort call
Dec 15	Patients seen Oct 1- Nov 30 data due Potential wrap up/summary call



March 12-14 | Phoenix, AZ

Save the Date



facs.org/cancerconference







Follow Us on Social Media









